<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:ifp="http://www.ifactory.com/press" ifp-element-xpath="/*[local-name() = 'urlset' and namespace-uri() = 'http://www.sitemaps.org/schemas/sitemap/0.9']"><ifp:contentType>PUBGEN_POST</ifp:contentType><url xmlns=""><loc>/view/post/news/asn-and-khi-show-support-for-kidneyx-in-meeting-with-hhs-secretary-alex-azar.xml</loc><ifp:title>ASN and KHI Show Support for KidneyX in Meeting with HHS Secretary Alex Azar</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/professional-13/asn-advocates-for-access-to-safe-alternatives-to-opioids--nsaids.xml</loc><ifp:title>ASN Advocates for Access to Safe Alternatives to Opioids, NSAIDS</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/communities-weekly-rewind--bilateral-renal-infarctions.xml</loc><ifp:title>Communities Weekly Rewind: Bilateral Renal Infarctions</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/communities-weekly-rewind--abo-incompatible-kidney-transplant--role-and-significance-of-igm-antibody-titers.xml</loc><ifp:title>Communities Weekly Rewind: ABO incompatible kidney transplant; role and significance of IgM antibody titers</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/otsuka-s-jynarque---tolvaptan--is-the-first-treatment-for-autosomal-dominant-polycystic-kidney-disease--adpkd--approved-by-fda.xml</loc><ifp:title>Otsuka’s JYNARQUE™ (tolvaptan) is the first treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) approved by FDA</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/a-call-for-kidney-week-abstract-submissions.xml</loc><ifp:title>A Call for Kidney Week Abstract Submissions</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/the-sixth-annual-kidney-health-initiative-stakeholders-meeting.xml</loc><ifp:title>The Sixth Annual Kidney Health Initiative Stakeholders Meeting</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/communities-weekly-rewind--igg1-lambda-mesangial-proliferative-gn.xml</loc><ifp:title>Communities Weekly Rewind: IgG1-lambda mesangial proliferative GN</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/communities-weekly-rewind--burnout-in-nephrology.xml</loc><ifp:title>Communities Weekly Rewind: Burnout in Nephrology</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/news-from-cms--telehealth-waiver-and-renamed-mips-category.xml</loc><ifp:title>News from CMS: Telehealth Waiver and renamed MIPS Category</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/all-of-us-research-program-announces-national-enrollment-date.xml</loc><ifp:title>All of Us Research Program Announces National Enrollment Date</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/nephrology-facing-workforce-shortage-issue.xml</loc><ifp:title>Nephrology facing workforce shortage issue</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/donald-w.-seldin--who-built-ut-southwestern-into-a-medical-powerhouse--dies-at-97.xml</loc><ifp:title>Donald W. Seldin, who built UT Southwestern into a medical powerhouse, dies at 97</ifp:title><lastmod>2021-07-13</lastmod></url><url xmlns=""><loc>/view/post/news/catalog-of-biases-in-health-studies.xml</loc><ifp:title>Catalog of Biases in health studies</ifp:title><lastmod>2021-07-13</lastmod></url></urlset>
